Stock Market Today: Stocks Drop on Troubling China Data, Bank Ratings Worries
The main benchmarks fell Tuesday, but healthcare stocks outperformed as Eli Lilly and Novo Nordisk surged.
Tuesday was a down day on Wall Street with stocks getting walloped across the board. Concerns over China's economy and the possibility that several big U.S. banks could see their credit ratings downgraded weighed on sentiment.
While the selling pressure was widespread for most of the session, healthcare stocks outperformed thanks to a few big movers.
Overnight, data from China showed exports from the world's second-largest economy fell 14.5% year-over-year in July, while imports dropped 12.4%.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
"The trade data from China was undoubtedly disappointing as it once again showed sluggish demand both domestically and externally," says Craig Erlam, senior market analyst at OANDA. China's economy is clearly in need of a boost, but it's likely authorities will engage in small, targeted measures that won't boost confidence among investors or households, Erlam adds.
Moody's lowers credit ratings for regional lenders, puts bigger banks under review
Meanwhile, Moody's Investors Services late Monday lowered the credit ratings for several regional lenders, including Pinnacle Financial Partners (PNFP, -2.1%) and M&T Bank (MTB, -1.5%). The ratings agency also said it is reviewing ratings for a number of larger U.S. banks, including Bank of New York Mellon (BK, -1.3%) and State Street (STT, -1.6%). The news sent shockwaves through the financial sector, with Goldman Sachs (GS, -2.1%) and JPMorgan Chase (JPM, -0.6%) being two of the worst Dow Jones stocks today.
"The development, which comes roughly five months after a handful of regional banks hit the skids, has sparked renewed concerns about the potential for additional bank failures and consolidations," says José Torres, senior economist at Interactive Brokers.
Additionally, the headlines hit as investors are trying to determine whether or not the Federal Reserve will continue to raise interest rates. "To that end, the Consumer Price Index (CPI) data to be released this Thursday could be a significant driver of investor sentiment and the outlook for the Fed's monetary policy," Torres adds.
Eli Lilly, Novo Nordisk pop on weight-loss drug news
Investors also took in the latest batch of earnings reports. On the positive side of the ledger, Eli Lilly (LLY) popped 14.9% after the drugmaker reported higher-than-expected second-quarter earnings of $2.11. Plus, revenue of $8.3 billion beat estimates thanks in part to strong sales of Eli Lilly's diabetes drug Mounjaro. LLY also got a boost after Novo Nordisk (NVO, +17.2%) said its obesity drug Wegovy reduced the chance of heart attacks by 20% in subjects who participated in a trial.
The data removes an "overhang" for the obesity treatment landscape, says BofA Securities analyst Geoff Meacham. The analyst, who reiterated his Buy rating on LLY, added that "today's results bolsters our confidence in the obesity commercial opportunity."
At the other end of the spectrum, Beyond Meat (BYND) tumbled 14.3% after the plant-based protein maker reported earnings. While the company reported a narrower-than-expected second-quarter loss of 83 cents per share, revenue of $102.1 million – down 30% on a year-over-year basis – came in below estimates. BYND also gave lower-than-anticipated full-year revenue guidance.
As for the major indexes, while they finished well off their intraday lows, the blue chip Dow Jones Industrial Average still closed down 0.5% to 35,314. The broader S&P 500 shed 0.4% to 4,499, and the tech-heavy Nasdaq Composite fell 0.8% to 13,884.
Related Content
Get Kiplinger Today newsletter — free
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.
With over a decade of experience writing about the stock market, Karee Venema is the senior investing editor at Kiplinger.com. She joined the publication in April 2021 after 10 years of working as an investing writer and columnist at Schaeffer's Investment Research. In her previous role, Karee focused primarily on options trading, as well as technical, fundamental and sentiment analysis.
-
Stock Market Today: The S&P 500 Reclaims the 6K Level
Investors see Scott Bessent as a safe shepherd of the economy as the president-elect burnishes his "Tariff Man" reputation.
By David Dittman Published
-
Why Is Warren Buffett Selling So Much Stock?
Berkshire Hathaway is dumping equities, hoarding cash and making market participants nervous.
By Dan Burrows Published
-
Stock Market Today: Stocks Pause as Investors Assess Fed Policy
The Federal Reserve met expectations with a quarter-point rate cut.
By David Dittman Published
-
Fed Cuts Rates Again: What the Experts Are Saying
Federal Reserve The central bank continued to ease, but a new administration in Washington clouds the outlook for future policy moves.
By Dan Burrows Published
-
Stock Market Today: Dow Jumps 1,500 Points on Election Outcome
The removal of election uncertainty unleashed a powerful rally in equity markets.
By Dan Burrows Published
-
If You'd Put $1,000 Into Google Stock 20 Years Ago, Here's What You'd Have Today
Google parent Alphabet has been a market-beating machine for ages.
By Dan Burrows Published
-
Stock Market Today: Markets March Higher as Strong Earnings Offset Weakness in Chips
Upbeat quarterly results helped stocks bounce back with broad-based gains.
By Dan Burrows Published
-
Stock Market Today: UnitedHealth Selloff Drags on Dow
While the main indexes ended in the red, Walgreens Boots Alliance had its best day since 2008.
By Karee Venema Published